MGNX News and Press, MacroGenics Inc. From 02/24/22

MacroGenics press release (NASDAQ:MGNX): FY GAAP EPS of -$3.37 misses by $0.10. Revenue of $77.45M (-26.2% Y/Y) misses by $6.13M. For further details see: MacroGenics GAAP EPS of -$3.37 misses by $0.10, revenue of $77.45M misses by $6.13M

Initiating Phase 1 dose escalation study of MGC018 in combination with lorigerlimab (formerly MGD019) in coming weeks Prioritizing MGD024 as lead CD3-based DART® molecule targeting CD123 and discontinuing development of flotetuzumab Presented encouraging preclinical...

ROCKVILLE, MD, Feb. 14, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial...

Biotechnology company, Synaffix B.V. enters into a technology agreement with MacroGenics (NASDAQ:MGNX) to gain access to Synaffix's clinical stage GlycoConnect antibody conjugation technology, HydraSpace polar spacer technology, as well as select toxSYN linker-payloads, each designed to ...

I-Mab (NASDAQ:IMAB) announces that the Center for Drug Evaluation (NYSE:CDE) of China has approved its Investigational New Drug (IND) submission for the initiation of a phase 2 trial in China for enoblituzumab (also known as TJ271) in combination with pembrolizumab (Keytruda) in patients with...

The following slide deck was published by MacroGenics, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: MacroGenics, Inc. 2021 Q3 - Results - Earnings Call Presentation

MacroGenics, Inc. (MGNX) Q3 2021 Earnings Conference Call November 2, 2021 4:30 PM ET Company Participants Chris James - Vice President of Investor Relations and Corporate Communications Scott Koenig - President and Chief Executive Officer Jim Karrels - Chief Financial Officer Conference Call...

Image source: The Motley Fool. MacroGenics (NASDAQ: MGNX) Q3 2021 Earnings Call Nov 02, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: MacroGenics (MGNX) Q3 2021 Earnings Call Transcript

MacroGenics (NASDAQ:MGNX): Q3 GAAP EPS of -$0.86 misses by $0.19. Revenue of $15.66M (-14.2% Y/Y) misses by $18.78M. Press Release For further details see: MacroGenics EPS misses by $0.19, misses on revenue

Investigational New Drug (IND) application submitted for MGD024, a next generation DART ® molecule targeting CD123 and CD3 for AML U.S. Food & Drug Administration (FDA) approves MacroGenics’ GMP manufacturing facility to produce MARGENZA ® drug subst...